Skip to main content

Advertisement

SpringerLink
Log in

Vitamin D Status Is Associated with Intestinal Inflammation as Measured by Fecal Calprotectin in Crohn’s Disease in Clinical Remission

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Vitamin D, as potential immune modulator, has been implicated as an environmental risk factor for Crohn’s disease (CD). Vitamin D status may be associated with disease risk, severity, activity, and progression. While associations between circulating 25OHD and markers of disease activity and inflammation in CD have been reported, the results are inconsistent.

Aim

To determine the association between vitamin D status and markers of disease activity and inflammation in CD.

Methods

One hundred and nineteen CD patients’ active and inactive diseases were enrolled in the cross-sectional study. Subject demographics and clinical data were collected. A serum sample was collected for 25OHD and CRP analysis, and a stool sample was collected for fecal calprotectin (FC) measurement.

Results

The mean serum 25OHD concentration of the group was 59.8 (24.9) nmol/L. After controlling for confounding variables, serum 25OHD inversely correlated with FC (r = −0.207, P = 0.030), particularly among those in clinical remission (r = −0.242, P = 0.022). The association between FC and 25OHD was further confirmed by linear regression (r = 31.3 %, P < 0.001). FC was lower in patients with 25OHD levels ≥75 nmol/L compared with levels <25 nmol/L [FC: 32.2 (16.3–98.2) vs 100.0 (34.4–213.5) μg/g, P = 0.004]. In the current study, however, 25OHD was not significantly associated with either CRP or CDAI.

Conclusion

Circulating 25OHD was significantly inversely associated with intestinal inflammation as determined by FC in CD. Subgroup analysis confirmed the association among those in clinical remission, but not in those with active disease. 25OHD was not associated with disease activity score (CDAI) or systemic inflammation (CRP). Vitamin D intervention studies are warranted to determine whether raising serum 25OHD levels in patients with CD may reduce intestinal inflammation as measured by FC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Suibhne TN, Cox G, Healy M, O’Morain C, O’Sullivan M. Vitamin D deficiency in Crohn’s disease: prevalence, risk factors and supplement use in an outpatient setting. J Crohns Colitis. 2012;6:182–188.

    Article  PubMed  Google Scholar 

  2. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.

    Article  PubMed  Google Scholar 

  3. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795–841.

    Article  PubMed  Google Scholar 

  4. Jørgensen SP, Agnholt J, Glerup H, et al. Clinical trial: vitamin D3 treatment in Crohn’s disease—a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther. 2010;32:377–383.

    Article  PubMed  Google Scholar 

  5. Ham M, Longhi MS, Lahiff C, Cheifetz A, Robson S, Moss AC. Vitamin d levels in adults with Crohn’s disease are responsive to disease activity and treatment. Inflamm Bowel Dis. 2014;20:856–860.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Ananthakrishnan AN, Khalili H, Higuchi LM, et al. Higher predicted vitamin D status is associated with reduced risk of Crohn’s disease. Gastroenterology. 2012;142:482–489.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Garg M, Rosella O, Lubel JS, Gibson PR. Association of circulating vitamin D concentrations with intestinal but not systemic inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2634–2643.

    Article  PubMed  Google Scholar 

  8. Jørgensen SP, Hvas CL, Agnholt J, Christensen LA, Heickendorff L, Dahlerup JF. Active Crohn’s disease is associated with low vitamin D levels. J Crohns Colitis. 2013;7:e407–e413.

    Article  PubMed  Google Scholar 

  9. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105:162–169.

    Article  CAS  PubMed  Google Scholar 

  10. Pedersen N, Thielsen P, Martinsen L, et al. eHealth: individualization of mesalazine treatment through a self-managed Web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014;20:2276–2285.

    Article  PubMed  Google Scholar 

  11. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1995;854:1–452.

  12. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A–36A.

  13. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–1930.

    Article  CAS  PubMed  Google Scholar 

  14. Laird E, McNulty H, Ward M, et al. Vitamin D deficiency is associated with inflammation in older Irish adults. J Clin Endocrinol Metab. 2014;99:1807–1815.

    Article  CAS  PubMed  Google Scholar 

  15. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–444.

    CAS  PubMed  Google Scholar 

  16. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.

    Article  CAS  PubMed  Google Scholar 

  17. D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–2224.

    Article  PubMed  Google Scholar 

  18. Ananthakrishnan AN, Cheng SC, Cai T, et al. Association between reduced plasma 25-hydroxy vitamin D and increased risk of cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:821–827.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Ulitsky A, Ananthakrishnan AN, Naik A, et al. Vitamin D deficiency in patients with inflammatory bowel disease: association with disease activity and quality of life. JPEN J Parenter Enteral Nutr. 2011;35:308–316.

    Article  CAS  PubMed  Google Scholar 

  20. Joseph AJ, George B, Pulimood AB, Seshadri MS, Chacko A. 25 (OH) vitamin D level in Crohn’s disease: association with sun exposure & disease activity. Indian J Med Res. 2009;130:133–137.

    CAS  PubMed  Google Scholar 

  21. Kelly P, Suibhne TN, O’Morain C, O’Sullivan M. Vitamin D status and cytokine levels in patients with Crohn’s disease. Int J Vitam Nutr Res. 2011;81:205–210.

    Article  CAS  PubMed  Google Scholar 

  22. Elliott PR, Lennard-Jones JE, Hathway N. Simple index of Crohn’s disease activity. Lancet. 1980;1:876.

    Article  CAS  PubMed  Google Scholar 

  23. Sipponen T, Kärkkäinen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221–1229.

    Article  CAS  PubMed  Google Scholar 

  24. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40–46.

    Article  PubMed  Google Scholar 

  25. Yang L, Weaver V, Smith JP, Bingaman S, Hartman TJ, Cantorna MT. Therapeutic effect of vitamin d supplementation in a pilot study of Crohn’s patients. Clin Transl Gastroenterol. 2013;4:e33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Raftery T, Martineau A, Greiller C, et al. Does vitamin D supplementation impact plasma cathelicidin, human beta defensin 2 and intestinal permeability in stable Crohn’s disease? Results from a randomised, double blind placebo controlled study. Proc Nutr Soc. 2013;72:E176.

    Article  Google Scholar 

  27. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern Med Rev. 2008;13:6–20.

    PubMed  Google Scholar 

  28. Røseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017–1020.

    Article  PubMed  Google Scholar 

  29. Molander P, af Björkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18:2011–2017.

  30. Gilman J, Shanahan F, Cashman KD. Determinants of vitamin D status in adult Crohn’s disease patients, with particular emphasis on supplemental vitamin D use. Eur J Clin Nutr. 2006;60:889–896.

    Article  CAS  PubMed  Google Scholar 

  31. de Bruyn JR, van Heeckeren R, Ponsioen CY, et al. Vitamin D deficiency in Crohn’s disease and healthy controls: a prospective case-control study in the Netherlands. J Crohns Colitis. 2014;8:1267–1273.

    Article  PubMed  Google Scholar 

  32. Driscoll RH, Meredith SC, Sitrin M, Rosenberg IH. Vitamin D deficiency and bone disease in patients with Crohn’s disease. Gastroenterology. 1982;83:1252–1258.

    PubMed  Google Scholar 

  33. Hollander D, Truscott TC. Mechanism and site of small intestinal uptake of vitamin D3 in pharmacological concentrations. Am J Clin Nutr. 1976;29:970–975.

    CAS  PubMed  Google Scholar 

  34. Leichtmann GA, Bengoa JM, Bolt MJ, Sitrin MD. Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in patients with both Crohn’s disease and intestinal resection. Am J Clin Nutr. 1991;54:548–552.

    CAS  PubMed  Google Scholar 

  35. Emmen JM, Wielders JP, Boer AK, van den Ouweland JM, Vader HL. The new Roche vitamin D total assay: fit for its purpose? Clin Chem Lab Med. 2012;50:1969–1972.

    Article  CAS  PubMed  Google Scholar 

  36. Cantorna MT, Munsick C, Bemiss C, Mahon BD. 1,25-Dihydroxycholecalciferol prevents and ameliorates symptoms of experimental murine inflammatory bowel disease. J Nutr. 2000;130:2648–2652.

    CAS  PubMed  Google Scholar 

  37. Froicu M, Cantorna MT. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol. 2007;8:5.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

TR is supported by the Irish Research Council (IRC) and Sarah Purser Medical Research Award from Trinity College, Dublin. These organizations had no involvement in the study other than grant funding. The authors acknowledge and thank the study participants.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Medicine, Trinity Centre for Health Science, St. James’s Hospital, Dublin, Ireland

    Tara Raftery, Megan Merrick, Nasir Mahmud & Maria O’Sullivan

  2. Department of Biochemistry, St. James’s Hospital, Dublin, 8, Ireland

    Martin Healy

  3. Department of Medicine, Trinity Centre for Health Science, Tallaght Hospital, Dublin, Ireland

    Colm O’Morain, Sinead Smith & Deirdre McNamara

  4. Department of Clinical Medicine, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin, 8, Ireland

    Maria O’Sullivan

Authors
  1. Tara Raftery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Megan Merrick
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Healy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nasir Mahmud
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Colm O’Morain
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sinead Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Deirdre McNamara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maria O’Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maria O’Sullivan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Raftery, T., Merrick, M., Healy, M. et al. Vitamin D Status Is Associated with Intestinal Inflammation as Measured by Fecal Calprotectin in Crohn’s Disease in Clinical Remission. Dig Dis Sci 60, 2427–2435 (2015). https://doi.org/10.1007/s10620-015-3620-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-015-3620-1

Keywords

Search

Navigation